Products: Glaukos

generic blue background

Product Literature

An entirely new class of surgery, Called Micro-Invasive Glaucoma Surgery (MIGS) is helping to transform the treatment of glaucoma. The iStent Trabecular Micro-Bypass Stent from Glaukos Corporation is the first and only MIGS device approved by the FDA. It is a powerful, new option that doctors are using to control IOP for glaucoma patients everywhere.


iStent is the smallest medical device known to be implanted in the human body. The dimensions of iStent are customized to optimize aqueous humor outflow while fitting naturally within the Schlemm’s canal. The ergonomic rail design protects and accesses underlying collector channels while iStent’s three retention arches ensure secure placement. iStent is heparin-coated to promote self-priming.


  • Length:1 mm
  • Height: 0.33 mm
  • Snorkel: 0.25 mm x 120 um (bore diameter)
  • Weight: 60 ug

iStent System

Each iStent system is comprised of a surgical-grade, nonferromagnetic, titanium micro-bypass stent preloaded in a single-use, sterile inserter.

The inserter has a secure, rotatable grip and reacquisition capability to facilitate manipulation and micro-targeted placement into the Schlemm's canal.

Two orientations of the iStent are available, one for the right eye (OD) and one for the left eye (OS).


iStent Mechanism of Action

The primary cause of elevated intraocular pressure (IOP) in patients with open-angled glaucoma is an abnormality of the trabecular meshwork. With up to 75% of resistance to outflow located in the juxtacanalicular tissue, increasing outflow through the inferonasal quadrants has a significant impact on lowering IOP due to the high presence of collector channels.

iStent safely improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. iStent improves outflow with a single bypass.